StemCell Institute
- Company typePublic
- Founded1999
- HeadquartersTokyo, Japan
- Headcount1–10
- GTM typeB2C
- OfferingServices
StemCell Institute firmographics
Firmographics- Name
- StemCell Institute
- Legal name
- 株式会社ステムセル研究所
- Website
- https://stemcell.co.jp
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where StemCell Institute is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
StemCell Institute business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Cord Blood and Cord Tissue Storage Service (HOPECELL): Recurring annual subscription fee for storage of cord blood and cord tissue collected at birth. Customers pay an initial processing fee and then annual renewal fees for long-term cryopreservation storage.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Monthly subscription plan starting at 2,980 yen/month for cord blood and cord tissue storage |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
StemCell Institute product offering
Product offeringCore offering
StemCell Institute provides private family cord blood and umbilical cord tissue banking services under the HOPECELL brand in Japan. The company collects cord blood and cord tissue at birth through a nationwide network of over 1,000 partner obstetric hospitals, transports samples to a Ministry of Health, Labour and Welfare licensed Cell Processing Center, and cryopreserves them in liquid nitrogen tanks at approximately -190°C for long-term storage. Customers subscribe to annual storage plans and can access their stored biological materials through the Extended Access Program (EAP) for future regenerative medicine applications.
Product overview
StemCell Institute operates as a specialized family cord blood and cord tissue bank, offering the HOPECELL service as Japan's only family bank that stores both cord blood and umbilical cord together. The core HOPECELL service provides collection, processing, and long-term cryogenic storage in liquid nitrogen at approximately -190°C. Additional services include the Family Supernatant Manufacturing Service for processing stored materials into therapeutic products, and the Extended Access Program (EAP) providing pathways for future clinical applications. The company holds a specific cell processing product manufacturing license from Japan's Ministry of Health, Labor and Welfare.
Differentiator
Problem solved
Functional benefit
Brands
- HOPECELL: Japan's only family bank service that stores both cord blood and cord tissue together at birth.
Products and services
- HOPECELL Cord Blood and Cord Tissue Combined Storage Japan's only family cord blood bank service that stores both cord blood and umbilical cord tissue together from a single birth, preserving hematopoietic stem cells and other cellular components for potential future medical use. Available to expectant parents in Japan through a network of over 1,000 partner obstetric hospitals.
- Collection to Storage Service (採取から保管まで) End-to-end service covering cord blood and cord tissue collection at birth, specialized transport to the cell processing center within 48 hours, processing in internationally compliant clean room environments, and long-term cryogenic storage in liquid nitrogen tanks at approximately -190°C.
- Family Supernatant Manufacturing Service (ファミリー上清製造サービス) Add-on service for existing storage customers to have stem cell-derived supernatant products manufactured from their stored biological materials for therapeutic applications.
- Extended Access Program (EAP / 拡大アクセス制度) Program providing an access pathway for stored cord blood to be used in clinical settings or regenerative medicine applications when approved treatments become available, enabling families to access their stored biological materials for therapeutic applications.
Companies that use StemCell Institute
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles3 records
StemCell Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
StemCell Institute partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and moderate.
- Southeast Asia Cell Bank Partners (Singapore)coreEstablished a cell processing center and cell storage center in Singapore for Southeast Asia cell bank business expansion. Completed in June 2026.
- iPS Portal Co., Ltd. (株式会社iPSポータル)coreJoint research partnership for establishing clinical-grade iPS cells from long-term stored cord blood. Joint study titled '臍帯血を用いた自家iPS細胞の製造及び保管プロセス開発と臨床応用に関する検討' (Development and clinical application of autologous iPS cell manufacturing and storage process using cord blood). Research presented at the 25th Japan Regenerative Medicine Society annual meeting demonstrated that cord blood stored for 20+ years can be used to establish clinical-grade iPS cells.
- Kochi University (高知大学)coreKochi University conducts Phase I clinical trials using autologous cord blood for cerebral palsy treatment, with cord blood stored by StemCell Institute. Also conducts sibling cord blood infusion studies. Clinical research results are published in peer-reviewed journals. The company supports these clinical trials through cord blood provision.
- Osaka University (大阪大学)moderateJoint research partner studying umbilical cord-derived cell applications for osteoarthritis treatment. Research presented at the 36th Japan Cartilage Metabolism Society. Osaka University Graduate School of Medicine, Sports Medicine department, exploring new treatment methods for knee osteoarthritis.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
StemCell Institute competitors and assessment
Company assessmentDirect peers
- ViaCord: Private family cord blood bank (Revvity/PerkinElmer). Direct competitor offering cord blood and cord tissue banking on a subscription basis, with similar value proposition around potential future therapeutic use.
- Cordlife Group: Singapore-listed cord blood banking group operating across Asia. Direct competitor in private family cord blood banking with similar subscription model and multi-country footprint; particularly comparable given StemCell's Singapore expansion.
- Cryo-Cell International: US-listed private cord blood and cord tissue bank. Operates a comparable subscription-based family banking model and is one of the few publicly traded pure-play cord blood banks, making it the closest listed comparable for StemCell Institute.
- Smart Cells International: UK-based private stem cell bank specializing in cord blood and tissue storage. Comparable subscription-based family banking model targeting expectant parents.
- Cells4Life: UK-based private cord blood and tissue bank offering combined cord + cord tissue storage and advanced processing techniques. Closely comparable product offering and customer profile.
- Cord Blood Registry (CBR): Largest US private family cord blood bank (owned by Cooper Companies). Competes directly in the same DTC subscription model targeting expectant parents, with comparable storage technology and hospital partner network.
Broad incumbents
- Japan Cord Blood Bank Network (JCBBN): Public cord blood banking network in Japan for unrelated-donor transplantation. Operates as the public-bank alternative to StemCell's private HOPECELL service; defines the regulatory and clinical landscape StemCell operates in.
Emerging players
- Beike Biotech: Asia-based stem cell therapy provider offering cord blood and umbilical cord MSC-derived regenerative treatments. Adjacent business model that could consume StemCell's stored samples as inputs for clinical applications.
- CryoHold: Latin America-focused cord blood bank group operating in Mexico and beyond. Comparable private banking model with geographic diversification strategy relevant to StemCell's SE Asia push.
Others
- Cell Therapy Sciences: Cord blood and tissue processing services provider for cryobanks. Adjacent ecosystem participant offering processing technology and logistics services relevant to StemCell's CPC operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
StemCell Institute social profiles
Digital presenceStemCell Institute compliance and trust
Trust signalCompliance3 records
StemCell Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
StemCell Institute leadership team
Management profileNumber of profiles
Profiles1 record
StemCell Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
StemCell Institute M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about StemCell Institute
What does StemCell Institute do?
StemCell Institute provides private family cord blood and umbilical cord tissue banking services under the HOPECELL brand in Japan. The company collects cord blood and cord tissue at birth through a nationwide network of over 1,000 partner obstetric hospitals, transports samples to a Ministry of Health, Labour and Welfare licensed Cell Processing Center, and cryopreserves them in liquid nitrogen tanks at approximately -190°C for long-term storage. Customers subscribe to annual storage plans and can access their stored biological materials through the Extended Access Program (EAP) for future regenerative medicine applications.
Is StemCell Institute a public or private company?
StemCell Institute is a public company. It is classified as public and is currently operating.
When was StemCell Institute founded?
StemCell Institute was founded in 1999. It employs 1 to 10 people.
Where is StemCell Institute based?
StemCell Institute is headquartered in Tokyo, Japan, in the Asia region.
How does StemCell Institute make money?
One revenue line is on record: cord Blood and Cord Tissue Storage Service (HOPECELL).
Who are StemCell Institute's main competitors?
Direct peers on record are ViaCord, Cordlife Group, Cryo-Cell International, Smart Cells International, Cells4Life and Cord Blood Registry (CBR). Japan Cord Blood Bank Network (JCBBN) is listed as a broad incumbent. Emerging players are Beike Biotech and CryoHold. Cell Therapy Sciences is listed as an others.
Does StemCell Institute have an API?
No public API is recorded for StemCell Institute.